Repligen Corporation $RGEN Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB cut its position in Repligen Corporation (NASDAQ:RGEN) by 15.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,600 shares of the biotechnology company’s stock after selling 5,089 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Repligen were worth $3,370,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in Repligen in the 1st quarter worth about $262,000. Jones Financial Companies Lllp raised its holdings in shares of Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after buying an additional 20,375 shares during the period. Bank of Nova Scotia boosted its position in shares of Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after buying an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after buying an additional 7,148 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Repligen stock opened at $132.02 on Friday. The firm has a 50 day simple moving average of $121.68 and a 200-day simple moving average of $136.56. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The stock has a market capitalization of $7.45 billion, a PE ratio of 146.69, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Royal Bank Of Canada assumed coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Barclays increased their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.